CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. [electronic resource]
Producer: 20080306Description: R87 p. digitalISSN:- 1465-542X
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Biomarkers, Tumor -- metabolism
- Biopsy, Fine-Needle
- Breast Neoplasms -- drug therapy
- CD40 Antigens -- metabolism
- Cyclophosphamide -- administration & dosage
- Epirubicin -- administration & dosage
- Female
- Fluorouracil -- administration & dosage
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Humans
- Mastectomy -- methods
- Mastectomy, Modified Radical
- Mastectomy, Segmental
- Middle Aged
- Neoadjuvant Therapy -- methods
- Neoplasm Staging
- Neoplasm, Residual
- Paclitaxel -- administration & dosage
- Predictive Value of Tests
- RNA, Messenger -- metabolism
- Receptor, ErbB-2 -- genetics
- Signal Transduction
- Transcription, Genetic
- Trastuzumab
- Treatment Outcome
- Up-Regulation
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.